Prescient Therapeutics (ASX: PTX)
Live Investor Briefing
Tuesday, 5th July 12pm (AEST)
Please join a special investor briefing with Prescient Therapeutics CEO and MD Steven Yatomi-Clarke.
In the session, Steven will discuss:
- Why Prescient is positioned at the forefront of a current revolution within oncology, the largest sector in healthcare at US$280 billion.
- How Prescient’s OmniCAR and CellPryme platforms can potentially enable and enhance cancer therapies as it moves from ‘treatment’ towards ‘personalised cure’.
- How the company can address an ecosystem of many potential partners leading togreater upside and revenue opportunities and diversified commercial risk.
- The ongoing progress of its targeted therapies, PTX-100 and PTX-200, through clinical studies and towards commercialisation.
This is a live and interactive online session, and participants are encouraged to ask questions. Joining only requires an internet connection. Spots are limited, so secure yours today.